One Injection Restored Mobility For Nearly Two Years…
Welcome to Kush™ Systems. Read on to discover how our technology is different... and can positively impact your veterinary practice and patient's lives.
Our Leading product is the Kush™ System, which is an injectable veterinary device, used in the treatment of osteoarthritis in equine and canine and is designed to prevent the occurrence and re-occurrence of joint pain from loss of cartilage or tissue-bone mechanical malfunction caused by joint dysfunction, not associated with infection, (e.g. lameness, osteoarthritis).
Kush™ System will augment synovial membrane function, without pharmacologic, chemical, or metabolic action. Our patented device particles act like micro-sized sponges, (75-100 microns in diameter) to fill up the joints synovium and lubricate the articulating surfaces, thereby making them slippery, (lubricious). The fluid's inherent physical characteristics combine with the particles durable structure to provide a soft springy cushion when force is applied to them, mimicking and augmenting the effects of a healthy synovium and healthy natural cartilage.
“Bella is enjoying the heck out of her new knee. Increased mobility overall. No more hesitance with going up stairs. Increased distance and time on walks. Can climb into minivan with minimal or no assistance. Overall, she looks like she did a year ago before her illness and surgery.”
Kush™ System's success is “Taking Osteoarthritis to the Finish Line”. Our device’s unique design is in the scaffolding matrix of animal proteins, (bovine elastin and collagen and porcine heparin), and how well it naturally integrates into the synovium. Kush™ System's active matrix of lubricating cushion prohibits cartilage-on-cartilage rubbing and/or bone-on-bone friction, thus protecting against future degeneration of the inner-joint surfaces.
Ease of daily activities after treatment have returned in as little as 24 hours and full efficacy shown in fewer than 14 days. Most pets who have been treated with the Kush™ System have no longer needed to take NSAIDS for pain relief associated with OA, as the pain diminished after the implantation (IA injection) of the device. The ability for pets to painlessly perform daily activities and return to normal exercise promotes increased blood flow and oxygen to the treated joint, which facilitates the natural production of synovial fluid and a healthy synovial membrane and cartilage.
The Kush™ System Supports Healthy Joints
Efficacy and Longevity
“One Dose, Lasted Long Enough”
Early OA, Degenerative Joint Disease and injury causing loss of sufficient membrane, detected and treated early, will show the best results for a Kush™ Systems candidate. The implantation rapidly adds relief from pain with cushioning support and lubrication to prevent future/further damage to cartilage and/or bone, and the patient returns to a better lifestyle. The ability to exercise and perform daily activities promotes good blood circulation and encourages the synovium to replenish itself and heal naturally, producing healthy synovial membrane and sufficient synovial fluid so that no more IA treatments may be needed. Reducing the frequency of moderately-invasive IA injections to surrounding tissue reduces risk of future infection to the treated joint.*
“Lasted the Entire Season”
Moderate OA that is treated with Kush™ Systems is effective in rapidly adding relief from pain with cushioning support and lubrication. Inflammation, not associated infection, is also reduced. As with early detection, further degeneration may be prevented depending on the disease advancement and the synovium and joint condition at the time of treatment. The patented Kush™ System has supported the joints of race horses that lasted all season. Veterinarians who treated canine as old as 13 years old have reported the Kush™ System comforting results lasting a full year.*
“Better Late Than Never”
Severe OA detected and diagnosed late is unfortunate. Many pet owners can’t afford joint replacement(s) for their pet, but more companion pet owners are willing to sacrifice up to $1,700.00 dollars for less invasive treatments. Both equine and canine, suffering from severe OA or DJD, will usually exhibit higher levels of lameness. Diminished quality of life and daily activities goes with the notable diminished cartilage and bone.
Many pets trying to overcome joint pain but not dealing with the cause of pain, may be suffering from systemically induced ailments, such as gastroenteritis, which can be a result of the long-term use of NSAIDs. Most Veterinarians have reported that a successful Kush™ System treatment will reduce or eliminate the need for NSAIDs. Kush™ System will fill the synovium for lubrication and cushioning support of joints natural articulation. However, bone fragmentation and other bone deterioration that has not been addressed may interfere with or prevent the full comforting benefits of the Kush™ System device*
*Pets of any age with beginning to moderate cartilage loss or damage will rapidly see the benefits of improved flexion and reduced lameness. Pets who once suffered are able to return to normal daily activities, high impact sports, competitive events and training, generally in as little as 2 days and experience full efficacy in less than two weeks. Typically, the lighter the body weight of the pet and the less impact on the treated joint, the greater the device longevity. Therefore, a heavier animal which performs activities or exercise of increased frequency, high impact or strenuous activity, the device longevity may be decreased.
Important Note: Kush™ System is a minimally-invasive IA injection which works fast and lasts long. Many manufacturers today offer IA injections to veterinarians to administer, which are intended for relief from joint pain, associated with OA. Some of the treatments require several injections over several weeks (boosters) to achieve similar results. Furthermore, many IA injections currently being sold have very limited periods of efficacy, less than a few months. Veterinarians using Kush™ System may be reducing the risk of infection associated with repeated or frequent use of moderately-invasive IA injections.